Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer (N24CUS)
2024-515259-40-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2024
- Modality
- Acoustic/Optical: Sonoporation, laser photoporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sonazoid in melanoma, breast cancer and head and neck cancer (HNC), sponsored by Netherlands Cancer Institute. Primary endpoint: Sensitivity and specificity of CEUS sentinel node localization. Planned start Dec 2024; status: authorised.
02
Drugs
sonazoid
03
Conditions
melanomabreast cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on 2024-515259-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515259-40-00.